TEVJF — TEVA PHARMACEUTICAL INDUSTRIES LTD

NYSE · Health Care · Pharmaceuticals · CIK 818686 · Israel
Last close
$30.34
Market Cap
$35.33B
52W High
$37.00
52W Low
$28.36
ADV30
20
Next earnings
2026-07-29
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders – chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 3,981,000,000 1,972,000,000 759,000,000 369,000,000 40,040,000,000 3,741,000,000 31,808,000,000
Dec 2025 4,711,000,000 2,656,000,000 1,269,000,000 480,000,000 40,748,000,000 3,556,000,000 32,834,000,000
Sep 2025 4,480,000,000 2,304,000,000 1,075,000,000 433,000,000 39,856,000,000 2,203,000,000 32,602,000,000
Jun 2025 4,176,000,000 2,102,000,000 899,000,000 282,000,000 40,131,000,000 2,161,000,000 33,297,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,714,000,000
Investing CF
$765,000,000
Financing CF
$-394,000,000
CapEx
$-542,000,000
Dividends Paid
Buybacks
EPS Diluted TTM
$1.14
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-13,394,000,000
Inventory
$3,176,000,000
Receivables
$3,393,000,000
ST Investments
EBIT TTM
$2,271,000,000
Pretax Income TTM
$1,366,000,000
Interest Exp TTM
$905,000,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$17,348,999,168
EBITDA
$5,002,999,808
Free Cash Flow
$2,611,375,104
Enterprise Value
$48,516,714,496
Total Cash
$3,740,999,936
Total Debt
$16,924,999,680
Shares Out
1,164,426,972
Trailing EPS
$1.34
Book Value
$7.07
ROE
21.6%
ROA
6.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 17,257,000,000 3,952,000,000 1,410,000,000 40,748,000,000 32,834,000,000 1,649,000,000
Dec 2024 16,544,000,000 3,364,000,000 -1,639,000,000 39,326,000,000 33,606,000,000 1,247,000,000
Dec 2023 15,845,000,000 3,194,000,000 -559,000,000 43,479,000,000 35,353,000,000 1,368,000,000
Dec 2022 14,925,000,000 2,690,000,000 -2,446,000,000 44,011,000,000 35,413,000,000 1,590,000,000

Peers — same industry

TickerNameMarket CapLastDaily %
ZTS Zoetis Inc. $34.46B $82.20
ALNY ALNYLAM PHARMACEUTICALS, INC. $39.75B $297.69
TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD $40.11B $34.45
BEIGF BeOne Medicines Ltd. $27.76B $22.50
TKPHF TAKEDA PHARMACEUTICAL CO LTD $48.14B $30.47

News headlines (Yahoo Finance, 1h cache)

Is Amneal a Buy Before Rytary Generic Erosion?
2026-06-09 15:56 · Yahoo
[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Gro
2026-06-09 04:30 · Yahoo
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
2026-06-08 12:00 · Yahoo
Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative?
2026-06-08 10:06 · Yahoo
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
2026-06-08 08:00 · Yahoo
Veeva Falcon AI Rollout Tests Investor Patience After Share Price Slide
2026-06-06 01:05 · Yahoo
Sector Update: Healthcare Stocks Gain Friday Afternoon
2026-06-05 17:50 · Yahoo
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
2026-06-05 17:31 · Yahoo
Teva Says AUSTEDO Improves Quality of Life in Huntington's Disease Study
2026-06-05 16:42 · Yahoo
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
2026-06-05 15:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.